A study of raloxifene and incidence of fractures was conducted among women with evidence of osteoporosis. The women were initially divided into two groups: those with and those without pre-existing fractures. The women were then randomized to raloxifene or placebo and followed for 3 years to determine the incidence of new vertebral fractures, with the results shown in Table 13.53. Among those with no preexisting fractures, compute the relative risk of new fractures among those randomized to raloxifene vs. placebo, along with its associated 95% CI.

TABLE 13.53 Comparison of fracture incidence between raloxifene- and placebo-treated women No pre-existing fractures Pre-existing fractures New fractures No new fractures Total New fractures No new fractures Total Raloxifene 34 1466 1500 Raloxifene 103 597 700 Placebo 68 1432 1500 Placebo 170 630 800 Total 102 2898 3000 Total 273 1227 1500